318 related articles for article (PubMed ID: 21067592)
1. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
[TBL] [Abstract][Full Text] [Related]
2. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
5. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC].
Peng S; Li X; Wang Y; Liu J
Zhongguo Fei Ai Za Zhi; 2017 Jul; 20(7):485-489. PubMed ID: 28738965
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Shi Y; Chen L; Li J; Lv YL; Sun Q; Wang LX; Jiao SC
Tumour Biol; 2011 Apr; 32(2):381-90. PubMed ID: 21086091
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
[TBL] [Abstract][Full Text] [Related]
9. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
12. Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.
Sorensen SF; Carus A; Meldgaard P
Lung Cancer; 2015 May; 88(2):167-73. PubMed ID: 25769883
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Rodrigo RS; Nathalie A; Elodie T; Gonzalo GA; Philippe T; Françoise D; Julien D; Angela C; Bérénice B; Jean-Yves B; Jean-Michel C; Jean B; Sylvie B; Axel le C
Eur J Cancer; 2011 Jun; 47(9):1319-27. PubMed ID: 21450455
[TBL] [Abstract][Full Text] [Related]
14. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
15. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
16. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
17. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
Park HL; Yoo IR; Boo SH; Park SY; Park JK; Sung SW; Moon SW
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1021-1026. PubMed ID: 30756189
[TBL] [Abstract][Full Text] [Related]
18. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
Zou ZQ; Du YY; Sui G; Xu SN
Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
20. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
